Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

(2010) S. Goto et al.   EUROPEAN HEART JOURNAL

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

(2009) David A. Morrow et al.   AMERICAN HEART JOURNAL

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale

(2009) The TRA•CER Executive and Steering Committees   AMERICAN HEART JOURNAL

Platelet thrombin receptor antagonism and atherothrombosis

(2009) D. J. Angiolillo et al.   EUROPEAN HEART JOURNAL

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

(2009)   LANCET

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

(2009) Richard C Becker et al.   LANCET